Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma

Blood

Volumn 89, Issue 3, 1997, Pages 789-793

  Barlogie, Bart ^a   Jagannath, Sundar ^b   Vesole, David H ^b   Naucke, Sally ^b   Cheson, Bruce ^b   Mattox, Sandy ^b   Bracy, Dwayne ^b   Salmon, Sydney ^b   Jacobson, Joth ^b   Crowley, John ^b   Tricot, Guido ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; INTERFERON; MELPHALAN; VINCRISTINE;

ADULT; AGED; ARTICLE; CHROMOSOME 11Q; CHROMOSOME 13; CYTODIAGNOSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE; TREATMENT PLANNING;

EID: 0031001279     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.3.789     Document Type: Article

References (20)

1. Barlogie B: Plasma cell myeloma, in Kipps T (ed): Hematology. William's Hematology (ed 5). Baltimore, MD, McGraw-Hill, 1995 p 1109
2. McElwain TJ, Powles RJ: High-dose intravenous melphalan for plasma-cell leukemia and myeloma. Lancet 2:822, 1983
3. Jagannath S, Vesole DH, Glenn L, Crowley J, Barlogie B: Low risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 80:1666, 1992
4. Barlogie B, Smith L, Alexanian R: Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310:1353, 1984
5. Gianni A, Siena S, Bregni M, Tarella C, Stern A, Pileri A, Bonadonna G: Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 2:580, 1989
6. Barlogie B, Velasquez S, Alexanian R, Cabanillas F: Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma. J Clin Oncol 7:1514, 1989
7. Greipp P, Raymond N, Kyle R, O'Fallon W: Multiple myeloma: Significance of plasmablastic subtype in morphological classification. Blood 65:305, 1985
8. Tricot G, Sawyer J, Jagannath S, Bracy D, Mattox S, Vesole D, Naucke S, Barlogie B: Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 86:4250, 1995
9. Salmon SE, Tesh D, Crowley J, Saeed S, Finley P, Milder M, Hutchins L, Coltman C, Bonnet J, Cheson B, Knost J, Samhouri A, Beckord J, Stock-Novack D: Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: A Southwest Oncology Group Study. J Clin Oncol 8:1575, 1990
10. Salmon SE, Crowley JJ, Grogan TM, Finley P, Pugh RP, Barlogie B: Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: A Southwest Oncology Group Study. J Clin Oncol 12:2405, 1994
11. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet G, Rossi JF, Casassus P, Thyss A, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R: High dose therapy in multiple myeloma: Final analysis of a prospective randomized study of the "Intergroupe Francais du Myelome" (IFM90). Blood 86:124a, 1995 (abstr, suppl 1)
12. Barlogie B, Jagannath, Vesole D, Tricot G, Naucke S, Copeland N, Crowley J: Total therapy (TT) for newly diagnosed multiple myeloma (MM). Blood 82:193a, 1993 (abstr, suppl 1)
13. Fermand JP, Ravaud P, Chevret S, Divine M, LeBlond V, Belanger C, Dreyfus F, Troussard X, Brechignac S, Mariette X, Brouet JC: High dose therapy (GDT) and autologous blood stem cell transplantation (ABSCT) versus conventional chemotherapy with GDT rescue in mutiple myeloma (MM): Results of a prospective randomized trial. Blood 86:205a, 1995 (abstr, suppl 1)
14. Westin J, Rodjer S, Turesson I, Cortelezzi A, Hjorth M, Zador G: Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: A randomized study. Br J Haematol 89:561, 1995
15. Powles R, Raje N, Cunningham J, Malpas J, Milan S, Horton C, Mehta J, Singhal S, Viner C, Treleaven J: Maintenance therapy for remission in myeloma with intron a following high dose melphalan and either an autologous bone marrow transplantation or peripheral blood cell rescue. Stem Cells 13:114, 1995
16. Kampmeier P, Spielberger R, Dickstein J, Mick R, Golomb H, Vardiman J: Increased incidence of second neoplasms in patients treated with interferon α 2b for hairy cell leukemia: A clinicopathologic assessment. Blood 83:2931, 1994
17. Sangfelt O, Osterborg A, Grander D, Anderbring E, Ost A, Mellstedt H, Einhorn S: Response to interferon therapy in patients with multiple myeloma correlates with expression of the bcl-2 oncoprotein. Int J Cancer 63:190, 1995
18. Gahrton G, Tura S, Ljungman P, Blade J, Brandt L, Cavo M, Facon T, Gratwohl A, Hagenbeek A, Jacobs P, Laurenzi A, Van Lint M, Michallet M, Nikoskelainen J, Reiffers J, Samson D, Verdonck L, Witte T, Volin L: Prognostic factor in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 13:1312, 1995
19. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B: Graft-versus-myeloma effect: Proof of principle. Blood 87:1196, 1996
20. Verdonck L, Lokhorst H, Dekker A, Nieuwenhuis H, Petersen E: Graft-versus-myeloma effect in two cases. Lancet 347:800, 1996